All In Biotech

Drug Trial Radar · NCT01785472

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Dec 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,438 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,438

Actual

Start

Apr 2013

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension

Conditions

  • Essential Hypertension

Interventions

  • LCZ696Drug

    LCZ696 200 mg tablet

  • OlmesartanDrug

    Olmesartan 20 mg capsule

  • Placebo of LCZ696Drug

    Placebo tablet of LCZ696 200 mg once daily

  • Placebo of OlmesartanDrug

    Placebo capsule of olmesartan 20 mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mgTime frame: baseline, 8 weeks

Locations

50 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Fuzhou, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, China

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, China

  • Novartis Investigative Site

    Fuzhou, Fujian, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Nanning, Guangxi, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, China

  • Novartis Investigative Site

    Nanchang, Jiangxi, China

  • Novartis Investigative Site

    Shenyang, Liaoning, China

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, China

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, China

  • Novartis Investigative Site

    Xi’an, Shanxi, China

  • Novartis Investigative Site

    Xi’an, Shanxi, China

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Hong Kong, Hong Kong, Hong Kong

  • Novartis Investigative Site

    Quezon City, Philippines

  • Novartis Investigative Site

    Quezon City, Manila, Philippines

  • Novartis Investigative Site

    Singapore, Singapore, Singapore

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Koyang, Kyunggi, South Korea

  • Novartis Investigative Site

    Douliu, Taiwan

  • Novartis Investigative Site

    Kaohsiung City, Taiwan

  • Novartis Investigative Site

    Kaohsiung City, Taiwan

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.